Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
34,503,199
-
Share change
-
-2,290,040
-
Total reported value
-
$709,497,850
-
Put/Call ratio
-
66%
-
Price per share
-
$20.60
-
Number of holders
-
109
-
Value change
-
-$40,255,166
-
Number of buys
-
55
-
Number of sells
-
65
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q1 2021
As of 31 Mar 2021,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
109 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,503,199 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Redmile Group, LLC, EVENTIDE ASSET MANAGEMENT, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., WELLINGTON MANAGEMENT GROUP LLP, STATE STREET CORP, VANGUARD GROUP INC, Vivo Capital, LLC, VR Adviser, LLC, and ACUTA CAPITAL PARTNERS, LLC.
This page lists
109
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.